Search for other papers by Petros Perros in
Google Scholar
PubMed
Search for other papers by Laszlo Hegedüs in
Google Scholar
PubMed
Introduction Thyroid eye disease (TED) is an autoimmune condition associated with Graves’ disease affecting approximately 0.1% of the population ( 1 , 2 ). TED can result in altered appearance and other significant symptoms, impacts
Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
Endocrinology Division, Department of Medicine, Walter Reed National Military Medical Center, Bethesda, Maryland, USA
Search for other papers by Henry B Burch in
Google Scholar
PubMed
Search for other papers by Petros Perros in
Google Scholar
PubMed
Search for other papers by Tomasz Bednarczuk in
Google Scholar
PubMed
Search for other papers by David S Cooper in
Google Scholar
PubMed
Search for other papers by Peter J Dolman in
Google Scholar
PubMed
Search for other papers by Angela M Leung in
Google Scholar
PubMed
Search for other papers by Ilse Mombaerts in
Google Scholar
PubMed
Search for other papers by Mario Salvi in
Google Scholar
PubMed
Search for other papers by Marius N Stan in
Google Scholar
PubMed
restore vision by reducing apical compression on the optic nerve. 2. Introduction Thyroid eye disease (TED) is an autoimmune condition closely related to Graves’ disease. It is characterized by endomysial interstitial edema, expansion, and
Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China
Search for other papers by Kenneth Ka Hei Lai in
Google Scholar
PubMed
Department of Ophthalmology, Salmaniya Medical Complex, Government Hospitals, Bahrain
Search for other papers by Fatema Mohamed Ali Abdulla Aljufairi in
Google Scholar
PubMed
Department of Ophthalmology, Vicente Sotto Memorial Medical Center, Cebu City, Philippines
Search for other papers by Jake Uy Sebastian in
Google Scholar
PubMed
Search for other papers by Yingying Wei in
Google Scholar
PubMed
Search for other papers by Ruofan Jia in
Google Scholar
PubMed
Search for other papers by Karen Kar Wun Chan in
Google Scholar
PubMed
Search for other papers by Elaine Yuen Ling Au in
Google Scholar
PubMed
Search for other papers by Alan Chun Hong Lee in
Google Scholar
PubMed
Search for other papers by Chiu Ming Ng in
Google Scholar
PubMed
Hong Kong Eye Hospital, Hong Kong Special Administrative Region, China
Search for other papers by Hunter Kwok Lai Yuen in
Google Scholar
PubMed
Search for other papers by Wilson Wai Kuen Yip in
Google Scholar
PubMed
Search for other papers by Alvin Lerrmann Young in
Google Scholar
PubMed
Search for other papers by George Pak Man Cheng in
Google Scholar
PubMed
Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China
Hong Kong Eye Hospital, Hong Kong Special Administrative Region, China
Search for other papers by Clement Chee Yung Tham in
Google Scholar
PubMed
Search for other papers by Chi Pui Pang in
Google Scholar
PubMed
Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China
Hong Kong Eye Hospital, Hong Kong Special Administrative Region, China
Search for other papers by Kelvin Kam Lung Chong in
Google Scholar
PubMed
Introduction Thyroid eye disease (TED), also known as thyroid-associated orbitopathy or Graves’ ophthalmopathy, is the most common extrathyroidal manifestation of Graves’ disease. It can also occur in euthyroid patients, known as euthyroid
Search for other papers by Susanne Neumann in
Google Scholar
PubMed
Search for other papers by Christine C. Krieger in
Google Scholar
PubMed
Search for other papers by Marvin C. Gershengorn in
Google Scholar
PubMed
primary autoantigens in orbital tissue in patients with thyroid eye disease (TED)/Graves’ orbitopathy (GO). The insulin-like growth factor 1 (IGF-1) receptor (IGF-1R) has been identified as another important player in the pathogenesis of TED. Functional
Endocrinology Unit, Graves’ Orbitopathy Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
Search for other papers by Ilaria Muller in
Google Scholar
PubMed
Search for other papers by Sara Maioli in
Google Scholar
PubMed
Search for other papers by Mirco Armenti in
Google Scholar
PubMed
Search for other papers by Laura Porcaro in
Google Scholar
PubMed
Ophthalmology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
Search for other papers by Nicola Currò in
Google Scholar
PubMed
Search for other papers by Elisabetta Iofrida in
Google Scholar
PubMed
Department of Specialistic Surgical Sciences, Otolaryngology and Head and Neck Surgery, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
Search for other papers by Lorenzo Pignataro in
Google Scholar
PubMed
Search for other papers by Jacopo Manso in
Google Scholar
PubMed
Search for other papers by Caterina Mian in
Google Scholar
PubMed
National Institute of Molecular Genetics (INGM) “Romeo and Enrica Invernizzi”, Milan, Italy
Search for other papers by Jens Geginat in
Google Scholar
PubMed
Search for other papers by Mario Salvi in
Google Scholar
PubMed
Ours is the first description of the immune cell profiling derived from the consecutive administration of alemtuzumab for multiple sclerosis and rituximab for thyroid eye disease. B-cell depletion induced by rituximab is an effective treatment for
Department of Women’s and Children’s Health, Pediatric Endocrinology Unit, Padua University Hospital, Padua, Italy
Search for other papers by Jacopo Manso in
Google Scholar
PubMed
Search for other papers by Simona Censi in
Google Scholar
PubMed
Search for other papers by Cristina Clausi in
Google Scholar
PubMed
Search for other papers by Ilaria Piva in
Google Scholar
PubMed
Search for other papers by Yi Hang Zhu in
Google Scholar
PubMed
Search for other papers by Alberto Mondin in
Google Scholar
PubMed
Search for other papers by Maria Chiara Pedron in
Google Scholar
PubMed
Search for other papers by Susi Barollo in
Google Scholar
PubMed
Search for other papers by Loris Bertazza in
Google Scholar
PubMed
Search for other papers by Giulia Midena in
Google Scholar
PubMed
Search for other papers by Raffaele Parrozzani in
Google Scholar
PubMed
Search for other papers by Caterina Mian in
Google Scholar
PubMed
Introduction Thyroid eye disease (TED) or Graves’ orbitopathy (GO) is an immune-mediated disorder of the eye in which cell-mediated response plays a crucial role and leads to oedema and deposition of glycosaminoglycans and collagens in the
Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China
Search for other papers by Haiyang Zhang in
Google Scholar
PubMed
Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China
Search for other papers by Shuo Wu in
Google Scholar
PubMed
Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China
Search for other papers by Shuyu Hu in
Google Scholar
PubMed
Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China
Search for other papers by Xianqun Fan in
Google Scholar
PubMed
Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China
Search for other papers by Xuefei Song in
Google Scholar
PubMed
Search for other papers by Tienan Feng in
Google Scholar
PubMed
Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China
Search for other papers by Huifang Zhou in
Google Scholar
PubMed
Introduction Thyroid eye disease (TED), also known as Graves’ ophthalmopathy, is the most common autoimmune orbital disease characterized by clinical presentations such as eyelid retraction, exophthalmos, periorbital edema, diplopia, and eye
Search for other papers by Jingyue Chen in
Google Scholar
PubMed
Search for other papers by Chenyan Li in
Google Scholar
PubMed
Search for other papers by Weiping Teng in
Google Scholar
PubMed
Search for other papers by Zhongyan Shan in
Google Scholar
PubMed
Search for other papers by Jun Jin in
Google Scholar
PubMed
Search for other papers by Yining Wei in
Google Scholar
PubMed
Search for other papers by Jing Sun in
Google Scholar
PubMed
Search for other papers by Yushu Li in
Google Scholar
PubMed
Search for other papers by Huifang Zhou in
Google Scholar
PubMed
Introduction Thyroid eye disease (TED), also known as thyroid-associated ophthalmopathy or Graves’ ophthalmopathy, is an infiltrative disorder affecting the retro-orbital and peri-orbital tissues caused by autoimmune system dysfunction. It
Search for other papers by Haitao Zhang in
Google Scholar
PubMed
Search for other papers by Hao Hu in
Google Scholar
PubMed
Search for other papers by Yueyue Wang in
Google Scholar
PubMed
Search for other papers by Xinjie Duan in
Google Scholar
PubMed
Search for other papers by Lu Chen in
Google Scholar
PubMed
Search for other papers by Jiang Zhou in
Google Scholar
PubMed
Search for other papers by Wen Chen in
Google Scholar
PubMed
Department of Ophthalmology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
Search for other papers by Weizhong Zhang in
Google Scholar
PubMed
Search for other papers by Xiaoquan Xu in
Google Scholar
PubMed
Search for other papers by Huanhuan Chen in
Google Scholar
PubMed
Introduction Thyroid eye disease (TED) is a specific autoimmune condition associated with inflammation of the thyroid, orbit, and periorbital tissues ( 1 , 2 ) that often endangers the patient’s vision and appearance ( 3 ). TED patients
Search for other papers by Pauline Campredon in
Google Scholar
PubMed
Multidisciplinary Thyroid Eye Consultation, Department of Endocrinology, Larrey University Hospital, Toulouse, France
Search for other papers by Philippe Imbert in
Google Scholar
PubMed
Search for other papers by Céline Mouly in
Google Scholar
PubMed
Search for other papers by Solange Grunenwald in
Google Scholar
PubMed
Search for other papers by Julien Mazières in
Google Scholar
PubMed
Search for other papers by Philippe Caron in
Google Scholar
PubMed
]. Rare cases of orbital myositis [ 4 ] and orbital inflammation resembling thyroid eye disease [ 5 - 8 ] have been associated with ipilimumab. During such treatment, thyroid-like orbitopathy was reported in euthyroid patients with absent [ 7 ], slightly